ASH 2023 | TargetRx to highlight advances of TGRX-678 in CML
2023-11-03 Views:
The 65th Annual Meeting of the American Society of Hematology (ASH) will be held in San Diego, USA, from December 9-12, 2023. As one of the world’s largest and most prestigious hematology academic conferences, the ASH Annual Meeting brings together well-known hematology experts from all over the world every year to share the most cutting-edge research progress and breakthrough clinical outcomes.
TGRX-678: Two latest research abstracts were accepted for oral presentation and poster display at the 65th ASH conference.
TGRX-678, a novel BCR-ABL allosteric inhibitor for the treatment of chronic myeloid leukemia (CML), is set to present the results of its Phase I clinical trial and preclinical research for the first time at the 2023 ASH Annual Meeting.
2023 ASH
Oral Presentation
Abstract Title
Safety and Efficacy of TGRX-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study
Submission ID
185977
Session Name
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches
Presenter
Qian Jiang,Peking University Peoples Hospital
Presentation Time
Monday, December 11, 2023 3:15 PM
Room
Marriott Marquis San Diego Marina, Pacific
2023 ASH
Poster Presentation
Abstract Title
TGRX-678, a Novel Allosteric Inhibitor of BCR-ABL1, Demonstrates Preclinical Anti-Leukemia Activity, High Oral Bioavailability and Synergism with Ponatinib to Suppress the Highly Resistant Compound Mutations
Submission ID
181391
Session Name
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster Ⅱ
Presentation Time
Sunday, December 10, 2023 6:00 PM - 8:00 PM
Location
San Diego Convention Center, Halls G-H
About TGRX-678
TGRX-678 is a novel BCR-ABL allosteric inhibitor for Chronic Myeloid Leukemia (CML). Unlike the marketed 1st-3rd generation BCR-ABL Tyrosine Kinase Inhibitors (TKIs) that act at the catalytic site, TGRX-678 was developed by specifically targeting the ABL myristol pocket (STAMP), thus locking the kinase into an inactive state and strongly inhibiting its kinase activity. TGRX-678 has the potential to treat refractory and resistant CML patients, including those who failed Ponatinib or Asciminib. TGRX-678 is currently undergoing clinical trials both in China and in US.